Equities

Natco Pharma Ltd

NATCOPHARM:NSI

Natco Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)952.05
  • Today's Change-21.45 / -2.20%
  • Shares traded495.46k
  • 1 Year change+73.51%
  • Beta0.6200
Data delayed at least 15 minutes, as of Mar 28 2024 10:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

  • Revenue in INR (TTM)38.28bn
  • Net income in INR12.78bn
  • Incorporated1981
  • Employees3.98k
  • Location
    Natco Pharma LtdNatco House, Road No 2, Banjara HillsHYDERABAD 500034IndiaIND
  • Phone+91 4 023547532
  • Fax+91 4 023545298
  • Websitehttp://www.natcopharma.co.in/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jubilant Pharmova Ltd66.22bn378.60m90.24bn1.03k235.19--15.401.362.422.42415.43--------64,045,440.00--3.95--4.7867.6466.570.51336.27--1.36--18.522.47-3.63-114.73--10.7410.76
Glenmark Life Sciences Ltd23.68bn5.19bn95.16bn1.82k18.33--16.704.0242.3642.36193.15--------12,982,110.00--------55.92--21.93----538.47----1.79--11.52------
Caplin Point Laboratories Ltd16.30bn4.38bn99.89bn777.0022.94--20.406.1357.3357.33213.53--------20,980,180.00--21.04--24.2556.4852.8427.0825.02--845.56--9.3715.5422.1325.4921.0531.8717.61
Granules India Ltd45.26bn3.95bn104.25bn3.65k26.36--17.432.3016.3216.32186.88--------12,400,240.00--11.15--16.5551.9449.358.7312.39--6.53--10.0819.8421.6725.1631.26-1.668.45
Eris Lifesciences Ltd18.61bn3.86bn114.72bn3.55k29.73--21.146.1628.3628.36136.57--------5,245,254.00--17.62--20.1282.0280.5720.3627.34--7.94----25.1014.52-5.905.38101.87--
Sun Pharma Advanced Research Co Ltd1.07bn-3.63bn119.52bn407.00------112.04-11.22-11.223.29--------2,621,133.00---59.13---119.2975.2179.70-340.66-116.46---400.34----73.9825.00-9.43---13.96--
Astrazeneca Pharma India Ltd11.97bn1.39bn133.21bn947.0095.63--86.1011.1355.7255.72478.78--------12,640,230.00--10.51--18.1059.9358.0511.649.11--132.84--11.8224.5011.8961.1930.826.29--
Concord Biotech Ltd9.71bn3.05bn159.10bn--52.88--44.3616.3928.7628.7692.74------------------79.70--31.38----------19.67--37.25------
Piramal Pharma Ltd77.82bn-333.40m169.88bn6.30k----24.432.18-0.3002-0.300263.15--------12,362,800.00--------64.29---0.4284----6.36----7.97---149.60------
Natco Pharma Ltd.38.28bn12.78bn170.52bn3.98k13.44--11.764.4570.8470.84212.24--------9,621,513.00--10.34--12.0478.2675.1133.3822.66--90.50--21.3439.204.22320.760.5428-19.11-8.34
Suven Pharmaceuticals Ltd11.68bn3.71bn172.37bn1.17k46.45--41.0414.7614.5814.5845.91--------10,023,860.00--------58.68--31.76----86.09----1.52---9.37------
Sanofi India Ltd28.51bn6.03bn186.87bn3.53k31.0018.4129.086.55261.78261.781,237.96440.801.512.2421.86--31.8422.4250.3530.2157.8855.6921.1521.030.897449.470.018458.182.920.573-2.859.64-10.3414.73
Piramal Enterprises Ltd79.98bn-20.16bn189.86bn12.22k------2.37-90.77-90.77339.88--------6,545,270.00--3.41--4.5147.2988.04-25.2126.30--0.2287--22.746.82-4.74528.3114.25-24.794.90
Pfizer Ltd22.19bn5.02bn191.91bn1.70k38.22--33.268.65109.76109.76485.08--------13,038,660.00--13.81--17.6363.0861.2122.6323.22--50.30--84.31-7.134.131.8611.62-8.7511.84
Alembic Pharmaceuticals Ltd61.18bn5.90bn193.58bn14.59k32.80--22.083.1630.0230.02311.22--------4,192,490.00--11.45--15.3971.1066.439.8013.65--10.21--25.266.5412.54-34.35-3.69-11.6114.87
Laurus Labs Ltd49.82bn1.88bn211.46bn5.75k112.88--37.134.243.483.4892.17--------8,659,934.00--11.78--19.7551.7348.414.0214.16--2.50--12.3722.3923.90-4.5236.3620.4231.95
Data as of Mar 28 2024. Currency figures normalised to Natco Pharma Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

13.21%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 20237.37m4.12%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 29 Feb 20244.76m2.66%
The Vanguard Group, Inc.as of 07 Mar 20243.46m1.93%
Tata Asset Management Ltd.as of 29 Feb 20241.63m0.91%
BlackRock Fund Advisorsas of 07 Mar 20241.45m0.81%
Kotak Mahindra Life Insurance Co., Ltd.as of 29 Feb 20241.39m0.78%
Dimensional Fund Advisors LPas of 07 Mar 20241.31m0.73%
Jupiter Asset Management Ltd.as of 30 Nov 2023943.17k0.53%
Norges Bank Investment Managementas of 31 Dec 2023768.12k0.43%
Mahindra Manulife Investment Management Pvt Ltd.as of 29 Feb 2024570.49k0.32%
More ▼
Data from 31 Dec 2023 - 20 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.